Trial Profile
Precision 2: an open explorative phase II, open label study of afatinib in the treatment of advanced cancer carrying an EGFR, a HER2 or a HER3 mutation
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Paclitaxel
- Indications Advanced breast cancer; Bladder cancer; Cervical intraepithelial neoplasia; Colorectal cancer; Endocrine gland neoplasms; Gastric cancer; Head and neck cancer; Liver cancer; Oesophageal cancer; Pancreatic cancer; Renal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms Precision 2
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 22 Aug 2017 New trial record